INTRODUCTION: Fluorine-18-labeled rhodamine B was developed as a potential positron emission tomography (PET) tracer for the evaluation of myocardial perfusion, but preliminary studies in mice showed no accumulation in the heart suggesting that it was rapidly hydrolyzed in vivo in mice. A study was therefore undertaken to further evaluate this hypothesis. METHODS: [(18)F]Fluoroethylrhodamine B was equilibrated for 2 h at 37 degrees C in human, rat and mouse serum and in phosphate-buffered saline. Samples were removed periodically and assayed by high-performance liquid chromatography. Based on the results of the stability study, microPET imaging and a biodistribution study were carried out in rats. RESULTS: In vitro stability studies demonstrated that [(18)F]fluoroethylrhodamine B much more stable in rat and human sera than in mouse serum. After 2 h, the compound was >80% intact in rat serum but <30% intact in mouse serum. The microPET imaging and biodistribution studies in rats confirmed this result showing high and persistent tracer accumulation in the myocardium compared with the absence of uptake by the myocardium in mice thereby validating our original hypothesis that (18)F-labeled rhodamines should accumulate in the heart. CONCLUSIONS: [(18)F]Fluoroethylrhodamine B is more stable in rat and human sera than it is in mouse serum. This improved stability is demonstrated by the high uptake of the tracer in the rat heart in comparison to the absence of visible uptake in the mouse heart. These observations suggest that (18)F-labeled rhodamines are promising candidates for more extensive evaluation as PET tracers for the evaluation of myocardial perfusion. Copyright 2010 Elsevier Inc. All rights reserved.
INTRODUCTION:Fluorine-18-labeled rhodamine B was developed as a potential positron emission tomography (PET) tracer for the evaluation of myocardial perfusion, but preliminary studies in mice showed no accumulation in the heart suggesting that it was rapidly hydrolyzed in vivo in mice. A study was therefore undertaken to further evaluate this hypothesis. METHODS:[(18)F]Fluoroethylrhodamine B was equilibrated for 2 h at 37 degrees C in human, rat and mouse serum and in phosphate-buffered saline. Samples were removed periodically and assayed by high-performance liquid chromatography. Based on the results of the stability study, microPET imaging and a biodistribution study were carried out in rats. RESULTS: In vitro stability studies demonstrated that [(18)F]fluoroethylrhodamine B much more stable in rat and human sera than in mouse serum. After 2 h, the compound was >80% intact in rat serum but <30% intact in mouse serum. The microPET imaging and biodistribution studies in rats confirmed this result showing high and persistent tracer accumulation in the myocardium compared with the absence of uptake by the myocardium in mice thereby validating our original hypothesis that (18)F-labeled rhodamines should accumulate in the heart. CONCLUSIONS:[(18)F]Fluoroethylrhodamine B is more stable in rat and human sera than it is in mouse serum. This improved stability is demonstrated by the high uptake of the tracer in the rat heart in comparison to the absence of visible uptake in the mouse heart. These observations suggest that (18)F-labeled rhodamines are promising candidates for more extensive evaluation as PET tracers for the evaluation of myocardial perfusion. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Marc C Huisman; Takahiro Higuchi; Sybille Reder; Stephan G Nekolla; Thorsten Poethko; Hans-Jürgen Wester; Sibylle I Ziegler; David S Casebier; Simon P Robinson; Markus Schwaiger Journal: J Nucl Med Date: 2008-03-14 Impact factor: 10.057
Authors: Ajay Purohit; Heike Radeke; Michael Azure; Kelley Hanson; Richard Benetti; Fran Su; Padmaja Yalamanchili; Ming Yu; Megan Hayes; Mary Guaraldi; Mikhail Kagan; Simon Robinson; David Casebier Journal: J Med Chem Date: 2008-04-19 Impact factor: 7.446
Authors: Igal Madar; Hayden T Ravert; Yong Du; John Hilton; Lana Volokh; Robert F Dannals; James J Frost; Joshua M Hare Journal: J Nucl Med Date: 2006-08 Impact factor: 10.057
Authors: Ming Yu; Mary T Guaraldi; Mahesh Mistry; Mikhail Kagan; Jennifer L McDonald; Kenneth Drew; Heike Radeke; Michael Azure; Ajay Purohit; David S Casebier; Simon P Robinson Journal: J Nucl Cardiol Date: 2007-10-22 Impact factor: 5.952
Authors: Mark D Bartholomä; Huamei He; Christina A Pacak; Patricia Dunning; Frederic H Fahey; Francis X McGowan; Douglas B Cowan; S Ted Treves; Alan B Packard Journal: Nucl Med Biol Date: 2013-09-04 Impact factor: 2.408
Authors: Xiaofeng Bao; Shuiyu Lu; Jeih-San Liow; Cheryl L Morse; Kacey B Anderson; Sami S Zoghbi; Robert B Innis; Victor W Pike Journal: Nucl Med Biol Date: 2012-08-14 Impact factor: 2.408
Authors: Mark D Bartholomä; Shaohui Zhang; Vamsidhar Akurathi; Christina A Pacak; Patricia Dunning; Frederic H Fahey; Douglas B Cowan; S Ted Treves; Alan B Packard Journal: Nucl Med Biol Date: 2015-06-18 Impact factor: 2.408
Authors: Mark D Bartholomä; Vijay Gottumukkala; Shaohui Zhang; Amanda Baker; Patricia Dunning; Frederic H Fahey; S Ted Treves; Alan B Packard Journal: J Med Chem Date: 2012-12-14 Impact factor: 7.446